Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
16.28
+0.49 (3.10%)
At close: Sep 2, 2026, 4:00 PM EDT
16.32
+0.04 (0.25%)
Pre-market: Sep 3, 2026, 8:51 AM EDT

Generate Biomedicines Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Cash & Equivalents
135.36121.65176.27
Short-Term Investments
322.0699.85217.36
Cash & Short-Term Investments
457.42221.5393.63
Cash Growth
--43.73%-
Receivables
--0.31
Prepaid Expenses
12.8412.5312.13
Restricted Cash
-0.341.43
Total Current Assets
470.25234.37407.49
Property, Plant & Equipment
82.3889.01101.07
Other Long-Term Assets
9.066.819.7
Total Assets
561.69330.18518.26

Liabilities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Accounts Payable
5.553.845.67
Accrued Expenses
22.7839.5419.34
Current Portion of Leases
13.6215.0116.72
Current Unearned Revenue
12.1721.1942.43
Other Current Liabilities
2.522.632.48
Total Current Liabilities
56.6482.286.63
Long-Term Leases
49.0153.5260.26
Long-Term Unearned Revenue
-4.5115.17
Other Long-Term Liabilities
-0.120.35
Total Liabilities
105.65140.35162.4

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Common Stock
0.130.050.05
Additional Paid-In Capital
1,26160.1738.45
Retained Earnings
-804.99-676.29-473.14
Comprehensive Income & Other
-0.130.110.12
Total Common Equity
456.05-615.97-434.52
Minority Interest
--7.23-0.57
Shareholders' Equity
456.05189.83355.86
Total Liabilities & Equity
561.69330.18518.26

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Total Debt
62.6368.5376.97
Net Cash (Debt)
394.79152.97316.66
Net Cash Growth
--51.69%-
Net Cash Per Share
4.813.056.50
Filing Date Shares Outstanding
128.3550.349.66
Total Common Shares Outstanding
128.2750.349.66
Working Capital
413.62152.16320.87
Book Value Per Share
3.56-12.24-8.75
Tangible Book Value
456.05-615.97-434.52
Tangible Book Value Per Share
3.56-12.24-8.75
Machinery
4842.9219.61
Construction In Progress
1.474.110.89
Leasehold Improvements
11.269.669.63
SEC Filings: 10-K · 10-Q